Immunizations and Immunity
Global Impact and Objectives of Immunization
Global Health Statistics:
An estimated people worldwide died in 2002 from diseases that are preventable by widely used vaccines.
An annual investment of could provide complete immunization coverage to every child in the developing world.
Core Learning Objectives:
Differentiate between the two primary systems of immunity (innate and adaptive).
Identify structural and functional elements of the innate immune system.
Compare and contrast humoral and cell-mediated adaptive immunity.
Explain B cell immune responses during initial (primary) and subsequent (secondary) antigenic exposures.
Differentiate active immunity from passive immunity and provide representative examples of each.
Explain the mechanism by which a vaccine confers resistance against an infectious organism.
List five major types of vaccines and provide specific examples for each type.
Define the term toxoid.
List currently recommended childhood and adult immunizations in the United States.
Define herd immunity and describe how it extends protection to nonimmunized individuals.
Historical Foundations of Vaccination
Smallpox and Edward Jenner (1796):
Immunization is widely considered one of the most successful applications of immunologic principles.
Vaccination is a procedure in which an infectious disease is prevented by prior exposure to a microorganism administered in a form that does not cause illness.
The first widespread use of vaccination occurred in the late 18th century against smallpox, a prevalent infectious disease in Europe.
In 1796, English physician Edward Jenner observed that dairymaids infected with cowpox appeared immune to smallpox.
Jenner tested this by taking fluid from a cowpox pustule of a young dairymaid and injecting it into the eight-year-old son of his gardener.
Six weeks later, Jenner inoculated the boy with fluid from a smallpox pustule; as anticipated, the boy did not contract smallpox.
Jenner repeated this experiment on other individuals and published his findings, establishing the principle that exposure to a harmless foreign agent can induce protective immunity against a pathogenic disease.
Fowl Cholera, Rabies, and Louis Pasteur (Late 19th Century):
Vaccination against other pathogens did not advance until the late 19th century through the work of Louis Pasteur.
Pasteur discovered attenuation while studying the bacterial organism responsible for fowl cholera.
After returning from a summer vacation, Pasteur injected chickens with an aged culture of the cholera organism. The chickens developed mild illness but recovered.
Pasteur subsequently injected these recovered chickens, along with a group of previously unexposed chickens, with a fresh, virulent bacterial culture.
The previously exposed chickens remained healthy, whereas the unexposed chickens developed cholera and died.
Pasteur hypothesized that aging altered the virulence of the organism without destroying its ability to protect against disease.
To honor Jenner's earlier work with cowpox, Pasteur named the aged culture a vaccine, derived from the Latin word vaccinus, meaning "pertaining to cows."
Pasteur developed additional vaccines using attenuated organisms, including the rabies vaccine.
While Jenner and Pasteur proved the efficacy of vaccination, the precise biological mechanisms underlying immunity were not fully understood until the 20th century.
Systems and Mechanisms of Immunity
Overview of Host Defenses:
Protection against infectious agents requires recognition of cellular changes and foreign microorganisms.
The body relies on two interconnected systems: the innate immune system and the adaptive immune system.
Innate Immune System:
Present from birth and serves as the immediate, first line of defense.
Response is nonspecific: it does not differentiate between specific pathogens and reacts identically regardless of the organism encountered.
Anatomical Barriers: Skin and mucosal membranes act as mechanical barriers that physically block pathogen entry.
Physiological Barriers:
Stomach acid provides an acidic environment that kills ingested microorganisms.
Chemical mediators, such as lysozymes and other hydrolytic enzymes in bodily secretions, destroy foreign organisms.
Phagocytic Cells:
Neutrophils and macrophages engulf and destroy invading microorganisms.
Phagocytosis is facilitated by complement proteins and antibodies that opsonize pathogens.
Inflammatory Processes: Generate antibacterial activity, increase blood flow, and recruit phagocytic cells to infected tissues.
Natural Killer (NK) Cells: Possess direct cytotoxic activity against tumor cells and certain virus-infected cells.
Phagocytic Clearance Dynamics:
Phagocytosis involves pathogen internalization by neutrophils or macrophages.
Intracellular destruction involves lysosomal enzymes, lowered internal pH, generation of hydrogen peroxide (), and elevated oxygen consumption (), resulting in digestive changes that cause microbial death.
Two Types of Adaptive Immunity: Cell-Mediated and Humoral
Adaptive Immune System Overview:
Also known as acquired or specific immunity.
Stimulated when innate immune defenses are insufficient to clear an infection.
Demonstrates high specificity for foreign agents by recognizing specific molecular structures called antigens.
Generates immunological memory, which forms the underlying mechanism of vaccine efficacy.
Primary cellular components are T lymphocytes and B lymphocytes.
Cell-Mediated Immunity:
Primarily involves T lymphocytes (T cells).
T cells originate from stem cells in the bone marrow and undergo maturation and differentiation in the thymus.
Functions primarily to eliminate intracellular pathogens, such as viruses and intracellular bacteria, as well as tumor cells.
T cells assist B cells by presenting protein antigens in a recognizable structure.
Activated T cells secrete cytokines—soluble proteins that mediate cell communication, regulation, and functional amplification within the immune network.
Subpopulations of T Lymphocytes:
Cytotoxic T cells: Directly eliminate infected or abnormal host cells.
Helper T cells: Coordinate immune responses and assist B cell activation.
Suppressor T cells: Down-regulate immune responses to maintain homeostasis.
Memory T cells: Persist long-term to mediate rapid recall responses upon re-exposure.
Humoral Immunity:
Mediated by B lymphocytes (B cells) and serves as the primary defense against extracellular pathogens.
B cells recognize specific regions on antigens known as epitopes or antigenic determinants.
Binding of an epitope to a B cell receptor triggers B cell differentiation into a plasma cell.
Plasma cells function as specialized factories that secrete immunoglobulins (antibodies) specific to the inducing antigen into the plasma.
Five Classes of Immunoglobulins: , , , , and .
Primary Antibody Functions:
Neutralize bacterial toxins.
Neutralize viruses to prevent viral entry into host cells.
Attach to bacterial cell surfaces (opsonization) to promote phagocytosis.
Activate complement protein cascades involved in the inflammatory response.
Dynamics of Antibody Responses
Primary Immune Response:
Initiated upon the body's first exposure to a specific foreign antigen.
Requires several days to a week post-exposure for antigen-specific antibodies to appear in the bloodstream.
Shortly after the initial response, antigen-specific antibodies appear.
Serum antibody titer rises, reaches a peak plateau, and subsequently declines as antibodies bind antigens for clearance or undergo catabolism into simpler molecules.
Secondary (Memory) Immune Response:
Mediated by memory B and T cells generated during the primary response.
Upon secondary exposure to the same pathogen, memory cells recognize the antigen rapidly.
Antibody production occurs significantly faster and produces markedly higher titers of antibodies compared to the primary response.
Enables rapid destruction and clearance of the pathogen before clinical illness can develop.
A third exposure further amplifies antibody production due to repeated immunological priming.
Active versus Passive Immunity
Active Immunity:
Occurs when an immunocompetent host's immune system directly encounters a foreign pathogen and synthesizes its own antibodies and memory cells.
Naturally Acquired Active Immunity: Results from clinical or subclinical natural infection with a pathogen.
Artificially Acquired Active Immunity: Conferred through vaccination.
Duration: Provides long-term protection due to the establishment of memory T and B cell populations.
Passive Immunity:
Involves the direct transfer of preformed antibodies from an immune donor to a nonimmune recipient.
Naturally Acquired Passive Immunity: Transplacental transfer of maternal antibodies to the fetus in utero.
Artificially Acquired Passive Immunity: Injection of exogenous immunoglobulin products (e.g., Hepatitis B immunoglobulin administered post-exposure).
Duration: Confers immediate but short-term protection; memory cells are not created, and protection wanes as transferred antibodies are catabolized.
Vaccine Types, Composition, and Mechanisms
Mechanism and Goals of Vaccination:
Vaccines mimic natural infections without causing disease, leveraging immunological memory and antigenic specificity.
Vaccine antigens stimulate memory B and T cell development to induce specific immunity, destroy invading pathogens, and neutralize bacterial exotoxins.
Full pathogen structures are not required because immune cells recognize discrete molecular epitopes.
Five Major Vaccine Categories:
Live, Attenuated Vaccines:
Contain living microorganisms weakened through abnormal laboratory culture conditions.
Retain antigenicity while losing pathogenic virulence.
Mimic natural infection closely, stimulating robust humoral and cell-mediated responses; usually require few doses for long-lasting protection.
Disadvantages: Small risk of reversion to a virulent strain; requires strict cold-chain refrigeration.
Examples: Measles, mumps, rubella (MMR), oral polio vaccine (Sabin), varicella.
Inactivated (Killed) Vaccines:
Produced by killing pathogens with heat or chemical agents (e.g., formaldehyde).
More stable and safer than live vaccines; do not require refrigeration and can be shipped freeze-dried.
Induce weaker immune responses, often requiring booster doses.
Examples: Cholera, rabies, influenza, hepatitis A, inactivated polio vaccine (Salk).
Toxoid Vaccines:
Created by inactivating bacterial exotoxins with formaldehyde.
Renders the toxin harmless while preserving its immunogenic epitopes to elicit toxin-neutralizing antibodies.
Examples: Tetanus toxoid, diphtheria toxoid.
Subunit Vaccines:
Composed only of specific, isolated epitopes or antigenic fragments rather than whole micro-organisms.
Minimizes adverse inflammatory reactions.
Often formulated with adjuvants (such as aluminum salts) that prolong antigen persistence at the injection site to enhance immune processing.
Examples: Hepatitis B, acellular pertussis, pneumococcal (Streptococcus pneumoniae) subunit.
Conjugate Vaccines:
Designed to enhance immunity against encapsulated bacteria possessing poorly immunogenic polysaccharide capsules.
Infant immune systems struggle to recognize isolated polysaccharide antigens.
Chemically couples (conjugates) the polysaccharide capsule antigen to a strongly immunogenic protein carrier, enabling robust recognition and T-cell-dependent immune processing.
Examples: Haemophilus influenzae type b (Hib), pneumococcal (Streptococcus pneumoniae) conjugate.
Factors Influencing Vaccine Efficacy:
Host nutritional status, underlying systemic illnesses, and age affect response quality.
Vaccines do not guarantee protection; a subset of vaccinated individuals will experience poor or absent immune responses ("poor responders").
Emerging and Future Vaccine Technologies
DNA Vaccines:
Utilize genetic sequences encoding target microbial antigens.
Plasmid DNA is introduced into host cells, instructing host cellular machinery to synthesize and express microbial antigens on their surface to provoke T cell and B cell activation.
Recombinant Vector Vaccines:
Employ attenuated non-pathogenic viral or bacterial vectors to deliver foreign pathogen DNA directly into host cells.
Under evaluation for diseases including influenza, malaria, rabies, and measles.
Pathogen Complexity and Evolutionary Challenges:
High mutation rates in viruses, such as Human Immunodeficiency Virus (HIV), continuously yield alterative antigenic variants, impeding universal vaccine design.
Complex parasites, such as the malarial parasite, express thousands of distinct antigens throughout multi-stage life cycles, complicating the identification of protective immunogenic targets.
Case Study: Clinical and Travel Immunization Considerations
Patient Profile and Clinical Scenario:
Patient: Maria Gonzalez, a 21-year-old pre-medical student at George Washington University and native of Washington, D.C.
Plan: Taking a gap year before her senior year to travel to South Africa and work as a relief worker in Darfur.
Duties: Assisting local clinicians, working in village immunization clinics, conducting basic health assessments, supporting hospital care for war-injured patients, and teaching hygiene and first aid to school children.
Pre-Travel Medical Evaluation:
Primary care physician reviewed accurate lifelong immunization records.
Recommended vaccinations prior to departure: Hepatitis A vaccine and Hepatitis B vaccine series.
Non-pharmacological preventive advice: Application of insect repellent (bug spray), avoidance of untreated drinking water, and avoidance of uncooked vegetables.
Family Comparison Notes: Maria had not previously received Hepatitis A or B vaccines. Her 2-month-old niece (Lucy) received Hepatitis B vaccination as part of standard infant care. Her 3-year-old nephew (Luis) received both Hepatitis A and B vaccination series during routine early childhood care.
Clinical and Public Health Rationale:
Diseases eradicated in developed nations remain endemic in international travel regions.
Official travel guidelines are published by resources such as the U.S. Department of State (
http://travel.state.gov/travel/tips/tips_1232.html).Vaccination guidelines evolve over time; smallpox vaccination was phased out following eradication, whereas universal infant Hepatitis A and B recommendations were introduced more recently.
Hepatitis A and B vaccines confer clinical protection lasting over 20 years. If traveling 30 years post-vaccination, revaccination/boosters would be required.
Preventive immunization is highly cost-effective relative to the medical, financial, and emotional costs of acute and chronic disease management.
Public Health, Disease Surveillance, and Healthy People 2010 Objectives
Historical Disease Eradication Milestones:
Smallpox: The last naturally acquired case occurred in 1977. The World Health Organization (WHO) recommended worldwide cessation of routine smallpox vaccination in 1979.
Poliomyelitis: Targeted for global eradication following widespread childhood immunization programs.
Healthy People 2010 Framework:
Promulgated by the U.S. Department of Health and Human Services (USDHHS).
Identified immunization as 1 of 10 Leading Health Indicators.
Contains 23 specific objectives related to immunization under Focus Area 14 (Immunization and Infectious Diseases):
14-1: Reduce or eliminate indigenous cases of vaccine-preventable diseases.
14-2: Reduce chronic hepatitis B virus infections in infants and young children (perinatal infections).
14-3: Reduce hepatitis B.
14-4: Reduce bacterial meningitis in young children.
14-5: Reduce invasive pneumococcal infections.
14-6: Reduce hepatitis A.
14-7: Reduce meningococcal disease.
14-8: Reduce Lyme disease.
14-15: Increase the proportion of international travelers who receive recommended preventive services when traveling in areas of risk for select infectious diseases: hepatitis A, malaria, and typhoid.
14-22: Achieve and maintain effective vaccination coverage levels for universally recommended vaccines among young children.
14-23: Maintain vaccination coverage levels for children in licensed day care facilities and children in kindergarten through the first grade.
14-24: Increase the proportion of young children and adolescents who receive all vaccines that have been recommended for universal administration for at least 5 years.
14-25: Increase the proportion of providers who have measured the vaccination coverage levels among children in their practice population within the past 2 years.
14-26: Increase the proportion of children who participate in fully operational population-based immunization registries.
14-27: Increase routine vaccination coverage levels for adolescents.
14-28: Increase hepatitis B vaccine coverage among high-risk groups.
14-29: Increase the proportion of adults who are vaccinated annually against influenza and ever vaccinated against pneumococcal disease.
14-30: Reduce vaccine-associated adverse events.
14-31: Increase the number of persons under active surveillance for vaccine safety via large linked databases.
U.S. Epidemiological Trends (2003–2004 Data):
In 2004, there were reported cases of diphtheria, rubella, or polio in the entire United States, and cases of tetanus among children under 5 years of age.
Haemophilus influenzae and Hepatitis B cases decreased among children under 5 years old from 2003 to 2004.
Measles, mumps, hepatitis A, and pertussis cases increased from 2003 to 2004.
Pertussis incidence increased in 2004 for the third consecutive year, reaching its highest level since 1959. of age-reported cases occurred in infants under 6 months of age (too young for complete acellular pertussis series), with an incidence rate of in this infant cohort.
Hepatitis A cases in children under 5 rose between 2003 and 2004, though overall incidence has declined dramatically since routine childhood vaccination recommendations were implemented in high-risk areas in 1996.
Recommended Childhood Immunization Schedule (United States)
Target Ages (Birth to 6 Years):
Milestone checkpoints: Birth, 1 month, 2 months, 4 months, 6 months, 12 months, 15 months, 18 months, 19–23 months, 2–3 years, and 4–6 years.
Standard Vaccine Abbreviations and Administration Ranges:
HepB (Hepatitis B): Administered at birth, 1–2 months, and 6–18 months.
Rota (Rotavirus): Administered at 2, 4, and 6 months.
DTaP (Diphtheria, Tetanus, Acellular Pertussis): Administered at 2 months, 4 months, 6 months, 15–18 months, and 4–6 years.
Hib (Haemophilus influenzae type b): Administered at 2 months, 4 months, 6 months, and 12–15 months.
PCV (Pneumococcal Conjugate Vaccine): Administered at 2 months, 4 months, 6 months, and 12–15 months.
IPV (Inactivated Poliovirus): Administered at 2 months, 4 months, 6–18 months, and 4–6 years.
Influenza: Recommended annually starting at 6 months of age.
MMR (Measles, Mumps, Rubella): Administered at 12–15 months and 4–6 years.
Varicella (Chickenpox): Administered at 12–15 months and 4–6 years.
HepA (Hepatitis A): 2-dose series started between 12 and 23 months.
MPSV4 (Meningococcal Polysaccharide Vaccine): Recommended for select high-risk groups between 2 and 6 years.
Adult and Targeted Population Vaccines:
Older adults and immunocompromised individuals: Annual influenza vaccine and pneumococcal vaccines (PCV/PPV).
Select occupational and military groups: Anthrax and smallpox vaccines (licensed for military personnel, specialized laboratory researchers, and designated first-responders; not distributed to the general public).
Herd Immunity and Barriers to Widespread Vaccine Coverage
Herd (Community) Immunity:
Defined as the resistance of a population to the spread of an infectious organism when a large proportion of individuals are immune.
Stops disease transmission chains, extending indirect protection to unimmunized individuals or poor responders.
Barriers in Developed Nations:
Access barriers among marginalized or underserved populations.
Language barriers and lack of non-English educational materials.
Immigrant populations facing limited access to primary care.
Decreased compliance with follow-up booster doses as children grow older.
Parental misperceptions and safety fears (e.g., unfounded concerns regarding "bad batches" causing disease; non-virulent U.S. vaccines carry no such risk).
Underestimation of personal risk for contracting vaccine-preventable diseases.
Barriers in Developing Nations:
Logistical hurdles, including lack of electrical infrastructure required to maintain strict cold chains for temperature-sensitive vaccines.
Poor transportation infrastructure and inadequate road networks in rural geographic regions.
Severe shortages of trained healthcare personnel to administer vaccines.
Key Biological and Public Health Terms
Biology Terms:
Adaptive Immunity: An immune response developed following exposure to a foreign agent that results in antigen recognition by T and B lymphocytes with subsequent development of specificity and memory.
Active Immunity: Adaptive immunity developed after exposure to an infection with a microorganism or following vaccination.
Adjuvant: A substance that enhances an immune response by prolonging exposure to the antigen within the body.
Antibody: A protein made in response to exposure to a foreign antigen that can bind to the antigen to facilitate elimination of the antigen.
Antigen: A foreign agent that can stimulate an immune response and bind to antibodies and T cells.
Attenuation: A process in which a pathogen is altered so it is less virulent.
Cell-Mediated Immunity: Immunity mediated by antigen-specific T lymphocytes and other cells that are involved in protecting against challenges such as intracellular organisms, viruses, and tumor cells.
Epitope: A small portion of an antigen that can stimulate an immune response and serve as a binding site for antibody.
Humoral Immunity: Immunity that involves antibody-mediated responses.
Immunity: A state of protection from disease created by innate and specific mechanisms.
Immunization: Protection of individuals against disease by vaccination.
Innate Immunity: Nonspecific mechanisms involved in the early response to pathogens that lacks specificity and involves anatomical, physiological, phagocytic, and inflammatory mechanisms.
Passive Immunity: Immunity acquired by natural or acquired transfer of preformed antibodies.
Toxoid: An altered toxin capable of inducing production of antibodies.
Vaccination: Injection of a vaccine in order to establish resistance to an infectious disease.
Vaccine: A preparation of antigenic material designed to induce an immune response and immunological memory when injected.
Public Health Terms:
Herd Immunity: Ability of a group to resist specific pathogens either through widespread natural exposure or through vaccination.
Incidence: Number of specified new events during a specified period in a specified population.
Study Questions, Discussion Topics, and Practical Exercises
Individual Student Research Questions:
Why must individuals be inoculated against influenza every year?
How would you develop an immune globulin for passive protection of someone exposed to rabies?
What are the impediments to creating a vaccine for the common cold?
How are the Sabin and Salk polio vaccines different, and why does the U.S. recommended immunization schedule no longer include the Sabin vaccine?
Small Group Discussion Topics:
Develop a timeline showing the changes in the U.S. immunization schedule over the last 30 years.
How does the U.S. immunization schedule differ from the schedules of other developed nations?
Entire Class Discussion Topics:
Despite evidence that immunizations are a cost-effective means of preventing specific infectious diseases, many people do not receive recommended immunizations. Discuss possible reasons for resistance to vaccination and suggest means of overcoming these obstacles to increase population coverage.
Applied Exercises and Activities:
South Pacific Resort Scenario: A previously undeveloped South Pacific island inhabited by two unmingled tribes with no prior external contact is designated for resort development. Design a complete immunization program to protect indigenous inhabitants against potential imported pathogen exposures.
Community Influence Campaign: Select a target population and design a comprehensive community campaign (including flyers and educational materials) promoting community-based influenza clinics, specifying objective metrics to evaluate campaign success.